Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis

* Participants with relapsing MS were eligible. Participants who met the criteria of MS based on McDonald criteria 2010 and International Pediatric Multiple Sclerosis Study Group (IPMSSG) criteria for pediatric MS, version of 2012 and had: * at least one relapse (or attack) in the 12 months preceding screening or, * at least two relapses (or attack) in the 24 months preceding screening. * Less than 18 years of age and greater than or equal to (\>=) 10 years of age at randomization. Specific for the Russian Federation from 18 December 2014 to 26 July 2016, less than or equal to 17 years of age and \>= 13 years of age at randomization. * Signed informed consent/assent obtained from participant and participant's legal representative (parents or guardians) according to local regulations. Exclusion criteria: * Expanded disability status scale score greater than 5.5 at screening or randomization visits. * Relapse within 30 days prior to randomization. * Treated with: * glatiramer acetate, interferons, or dimethyl fumarate within 1 month prior to randomization. * fingolimod, or intravenous immunoglobulins within 3 months prior to randomization. * natalizumab, other immunosuppressant or immunomodulatory agents such as cyclophosphamide, azathioprine, cyclosporine, methotrexate, mycophenolate, within 6 months prior to randomization. * cladribine or mitoxantrone within 2 years prior to randomization. * Treated with alemtuzumab at any time. * History of human immunodefici…